Diagnostics company Guardant Health (NASDAQ: GH) will be reporting results this Thursday after market hours. Here’s what to expect.

Guardant Health beat analysts’ revenue expectations by 12.6% last quarter, reporting revenues of $265.2 million, up 38.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Is Guardant Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Guardant Health’s revenue to grow 34.6% year on year to $271.7 million, improving from the 30.2% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.47 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Guardant Health has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 9.1% on average.

Looking at Guardant Health’s peers in the testing & diagnostics services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 1.9%, and NeoGenomics reported revenues up 10.6%, topping estimates by 1%. Quest traded up 9.4% following the results.

Read our full analysis of Quest’s results here and NeoGenomics’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the testing & diagnostics services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. Guardant Health is down 7.5% during the same time and is heading into earnings with an average analyst price target of $125 (compared to the current share price of $107.54).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.